Researchers discover treatable cause of severe anemia associated with a cancer therapy

Researchers discover treatable cause of severe anemia associated with a cancer therapy. Researchers at the Mount Sinai Tisch Cancer Center have identified a previously underrecognized folate deficiency that may cause severe anemia in some patients receiving PARP inhibitors, a widely used class of targeted cancer therapies.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: Researchers at the Mount Sinai Tisch Cancer Center have identified a previously underrecognized folate deficiency that may cause severe anemia in some patients receiving PARP inhibitors, a widely used class of targeted cancer therapies. Their findings, published in the latest issue of the journal Blood Red Cells & Iron, suggest that routine screening and treatment with folic acid could help many patients avoid blood transfusions, hospitalizations and interruptions to their cancer treatment.

• Ponto de atenção: researchers.
• Ponto de atenção: discover.
• Ponto de atenção: treatable.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.